Electra Therapeutics, Inc. (ETRA) reported the closing of its initial public offering of common stock on September 21, 2026. The company sold 23,333,334 shares of common stock at $15.00 per share, generating approximately $350.0 million in gross proceeds before underwriting discounts and expenses.
In connection with the IPO closing, Electra Therapeutics’ stockholders and board put into effect an amended and restated certificate of incorporation and amended and restated bylaws. The company’s common stock trades on The Nasdaq Global Select Market under the symbol ETRA.
Electra Therapeutics, Inc. (ETRA) is conducting an initial public offering of 23,333,334 shares of common stock at $15.00 per share, raising gross proceeds of $350.0 million and approximately $325.5 million in proceeds before expenses, with Nasdaq Global Select Market listing under the symbol ETRA. Underwriters have a 30‑day option to purchase up to 3,500,000 additional shares. Electra is a late clinical‑stage biopharmaceutical company developing precision medicines that target signal regulatory proteins (SIRP) to selectively deplete disease‑driving immune cells in immune‑mediated diseases and cancer. Lead candidate ipsoprubart is in a global Phase 2/3 registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) after Phase 1b data showing 100% 8‑week overall survival and overall response in 12 frontline malignancy‑associated HLH patients; it has FDA Breakthrough Therapy and EMA PRIME designations. Second candidate ELA822 is in a Phase 1 trial in Europe targeting chronic T cell‑mediated diseases. The company has no approved products, reported a net loss of $62.0 million in 2025 and an accumulated deficit of $221.9 million as of June 30, 2026, and its auditors included a going‑concern explanatory paragraph; management expects existing cash plus IPO proceeds to fund operations into 2029.
Electra Therapeutics, Inc. (ETRA) received an initial ownership report from OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, reflecting indirect holdings of Series A, B and C Convertible Preferred Stock that are convertible into Common Stock upon the closing of the company’s initial public offering.
The reported positions correspond to 2,002,310 underlying shares of Common Stock from Series A, 1,087,934 from Series B, and Series C holdings corresponding to 758,279 and 1,703,314 underlying Common shares. All preferred shares automatically convert into Common Stock on a 1-for-1 basis at the IPO closing and have no expiration date.
The securities are held by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed-related general partners and OrbiMed Advisors potentially deemed to share voting and investment power. Each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest, and OrbiMed has designated Carl L. Gordon to serve on Electra Therapeutics’ board of directors.
Electra Therapeutics, Inc. (ETRA) reported initial insider holdings for Principal Accounting Officer David J. Tucker. He holds two employee stock options for common stock: one covering 114,000 shares at an exercise price of $4.96 per share expiring on April 8, 2036, and another covering 73,402 shares at an exercise price of $15.00 per share expiring on September 16, 2036. The first option vests with one-quarter of the shares vesting one year after March 30, 2026 and the remainder in equal monthly installments over the following three years and is early exercisable subject to the company’s repurchase right. The second option vests in equal monthly installments beginning on September 17, 2026.
Electra Therapeutics, Inc. (ETRA) reported that director Matthew K. Fust holds three director stock options covering its common stock. These options allow the purchase of 59,086 shares at $4.40 per share expiring November 16, 2033, 77,714 shares at $4.96 per share expiring February 12, 2036, and 22,632 shares at $15.00 per share expiring September 16, 2036.
One grant vests over four years starting October 16, 2023 with monthly vesting thereafter and is early exercisable subject to the company’s right of repurchase; another vests monthly from February 1, 2026 on the same early-exercise and repurchase terms; the third vests on the earlier of September 17, 2027 or the next annual stockholder meeting.
Electra Therapeutics, Inc. (ETRA) reported an initial statement of beneficial ownership for Chief Medical Officer Dao Kim-Hien, detailing holdings of employee stock options to purchase common stock. The positions include options over 62,631 and 23,634 shares at $4.40, 103,992 and 47,269 shares at $5.05, 309,676 shares at $4.96, and 155,979 shares at $15.00, expiring between 2033 and 2036. Footnotes state these options vest over time in monthly installments and are early exercisable, subject to the issuer’s right of repurchase.
Electra Therapeutics, Inc. (ETRA) reports that Chief Scientific Officer Parry Graham beneficially owns several employee stock options and Series A Convertible Preferred Stock. The options cover blocks of common stock at exercise prices of $4.40, $4.96, and $15.00 with expirations from 2033 to 2036, plus Series A Convertible Preferred Stock that will automatically convert into common stock upon the company’s initial public offering.
Electra Therapeutics, Inc. (ETRA) had its Principal Accounting Officer, Parry Graham, file an initial statement of beneficial ownership reporting two employee stock options over its common stock. One option covers 114,000 shares at an exercise price of $4.96 per share, expiring on April 8, 2036, and is early exercisable with vesting beginning one year after March 30, 2026. A second option covers 73,402 shares at an exercise price of $15.00 per share, expiring on September 16, 2036, with monthly vesting commencing on September 17, 2026. No purchases or sales of common stock are reported in this filing.
Electra Therapeutics, Inc. (ETRA) reported the initial equity holdings of Chief Technical Officer Gary S. Koe. He holds several employee stock options over common stock with exercise prices ranging from $4.40 to $15.00 per share and expirations between March 23, 2032 and September 16, 2036, with varying monthly vesting and some fully vested or early exercisable subject to the company’s repurchase rights. He also holds Series A Convertible Preferred Stock that will automatically convert into 63,656 common shares upon the closing of the company’s initial public offering.
Electra Therapeutics, Inc. (ETRA) reported initial insider holdings for director Carl L. Gordon. The filing lists indirect interests in Series A, B and C Convertible Preferred Stock, each automatically convertible into Common Stock on the closing of Electra’s initial public offering, with no expiration date.
The preferred shares are held by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.; related OrbiMed entities, including OrbiMed Advisors LLC and its management committee (which includes Carl L. Gordon), may be deemed to share voting and investment power, while each individual member disclaims beneficial ownership. Gordon also holds a Director Stock Option over 22,632 shares of Common Stock at an exercise price of $15.00 per share, vesting on the earlier of September 17, 2027 and the next annual stockholder meeting, and expiring on September 16, 2036.